July 13, 2026 Sana Biotechnology Makes Headlines with Promising Long-Term Data on Type 1 Diabetes Treatment Sana Biotechnology's recent study reveals promising long-term results for its UP421 therapy, suggesting a potential functional cure for type 1 diabetes without immunosuppressants. The findings highlight significant advancements in diabetes management, with plans for further clinical trials on their gene-modified therapy, SC451.
July 01, 2026 Sana Biotechnology Announces Key Presentation at EASD Annual Meeting 2026 Sana Biotechnology is set to present pioneering data on its UP421 islet cell therapy at the EASD Annual Meeting 2026. This innovative approach may eliminate the need for immunosuppression in type 1 diabetes treatments, marking a significant advancement in patient care.
May 27, 2026 Sana Biotechnology Inc. Announces Upcoming Investor Presentations in June 2026 Sana Biotechnology, Inc. will participate in two major investor conferences in June 2026, presenting its strategic vision and updates on innovative cell therapies. Investors can access live webcasts of the events and replays for 30 days.
May 15, 2026 Sana Biotechnology Secures $69 Million Through At-the-Market Share Sale Sana Biotechnology has raised $69 million through the sale of 21.6 million shares, significantly boosting its financial resources. This capital will support its mission to develop cutting-edge cellular therapies and extend its cash runway into mid-2027.
May 05, 2026 Sana Biotechnology to Showcase Innovations at BofA Securities Healthcare Conference Sana Biotechnology will present at the BofA Securities 2026 Healthcare Conference, showcasing its mission to innovate patient care through engineered cellular therapies. CEO Steve Harr will provide updates on the company’s vision and research efforts, emphasizing their commitment to transforming treatment standards.
April 27, 2026 Sana Biotechnology Inc. Showcases Innovative CAR T Technology at ASGCT 2026 Sana Biotechnology's SG293 CAR T technology highlights its innovative approach to *in vivo* therapies for B-cell malignancies and autoimmune disorders. This method aims to enhance safety and efficacy by targeting CD8+ T cells while minimizing off-target effects. The preclinical data will be presented at ASGCT 2026, marking a significant advancement in cellular therapies.
April 13, 2026 Sana Biotechnology Partners with Mayo Clinic to Revolutionize Type 1 Diabetes Treatment Sana Biotechnology has teamed up with Mayo Clinic to advance SC451, a revolutionary hypoimmune-modified pancreatic islet cell therapy for Type 1 diabetes. This collaboration aims to enhance clinical trial processes and optimize treatment protocols, promising a future where insulin dependence may be significantly reduced.
March 13, 2026 Sana Biotechnology Reports Promising 14-Month Results in Type 1 Diabetes Study Sana Biotechnology reports significant 14-month findings from its islet cell transplantation study for type 1 diabetes, indicating sustained functionality and safety of transplanted cells without immunosuppression. The results pave the way for innovative treatments that could revolutionize diabetes management.
March 03, 2026 Sana Biotechnology Inc. Reports Encouraging Financial Results for Q4 and Full Year 2025 Sana Biotechnology Inc. reported encouraging Q4 2025 results, highlighting progress in its clinical pipeline for type 1 diabetes and blood cancers. The company also noted a strategic financial management approach, reducing losses while advancing innovative therapies. Leadership changes aim to enhance operational efficiency as Sana prepares for significant clinical trials ahead.
March 03, 2026 Sana Biotechnology Inc. Releases 2025 Annual Report: A Year of Strategic Focus and Financial Challenges Sana Biotechnology's 2025 annual report reveals significant advancements in engineered cell therapies amidst ongoing financial challenges, including substantial net losses. The company focuses on promising products like SC451 and SG293, while addressing macroeconomic factors impacting its operations.
February 23, 2026 Sana Biotechnology Set to Showcase Innovations at Upcoming Investor Conferences Sana Biotechnology will showcase its latest developments at two investor conferences in March 2026. Stakeholders can access live webcasts and gain insights into the company's innovative cell therapies and strategic vision for transforming patient care.
February 17, 2026 Sana Biotechnology Welcomes Brian Piper as New CFO Sana Biotechnology has appointed Brian Piper as its new CFO, leveraging his extensive 25-year experience in biopharmaceutical finance. His leadership is expected to drive financial stability and support clinical developments targeting type 1 diabetes and B-cell diseases.
January 07, 2026 Sana Biotechnology to Showcase Innovations at J.P. Morgan Healthcare Conference Sana Biotechnology will present its innovations in engineered cell therapies at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. Led by CEO Steve Harr, the presentation will be accessible via live webcast, with a replay available for 30 days, highlighting Sana's commitment to transforming patient care.
December 08, 2025 Sana Biotechnology Advances Gene Editing with Breakthrough Publication Sana Biotechnology has published a pivotal study in *Nature Biotechnology* showcasing their innovative gene editing technology that targets hematopoietic stem cells. This approach promises to transform treatments for diseases like sickle cell and beta thalassemia by enabling direct gene editing in the bone marrow, reducing risks associated with traditional methods.
November 24, 2025 Sana Biotechnology Inc. Gears Up for December Investor Conferences Sana Biotechnology, Inc. is gearing up for two significant investor conferences in December 2025, where it will discuss its innovative cell engineering strategies. Presentations will be led by CEO Steve Harr, providing insights into the company's future plans. Webcasts will be available for those unable to attend live.
November 06, 2025 Sana Biotechnology Inc. Reports Third Quarter 2025 Financial Results and Strategic Developments Sana Biotechnology reported its Q3 2025 financial results, emphasizing a strategic focus on two key therapies for type 1 diabetes and CAR T cell treatment. The company has suspended less prioritized programs to enhance resource allocation and showcased promising clinical advancements.
November 06, 2025 Sana Biotechnology Inc. Reports Q3 2025 Financial Results: Focused on Innovation Amidst Strategic Changes Sana Biotechnology's Q3 2025 report shows a reduced net loss of $42.15 million and a strategic pivot towards its SC451 and SG293 platforms. Despite ongoing challenges, the company is focused on innovation in cell therapies and improving its financial health.
November 04, 2025 Sana Biotechnology to Present at TD Cowen Immunology & Inflammation Summit Sana Biotechnology will present at the TD Cowen Immunology & Inflammation Summit on November 12, 2025, showcasing its advances in engineered cell therapies. CEO Steve Harr will discuss the company’s strategic vision and significant medical challenges they aim to address.
August 11, 2025 Sana Biotechnology Inc. Reports Q2 2025 Financial Results Sana Biotechnology Inc. reported a net loss of $93.8 million in Q2 2025, amidst strategic shifts focusing on T1D and autoimmune diseases. The company is advancing multiple clinical trials while navigating financial challenges and seeking additional funding.
May 08, 2025 Sana Biotechnology Inc. Reports 2025 Q1 Financial Results: A Strategic Shift and Clinical Advancements Sana Biotechnology Inc. reported its Q1 2025 financial results, highlighting a strategic pivot towards innovative therapies for type 1 diabetes and autoimmune diseases. Despite a reduced net loss, the company faces liquidity challenges and the necessity for further funding as it advances its clinical trials.
March 17, 2025 Sana Biotechnology Inc. Reports 2024 Annual Results: A Year of Strategic Refinement and Financial Challenges Sana Biotechnology's 2024 annual report reveals a focus on engineered cell therapies for chronic diseases, despite financial losses. Key developments include ongoing clinical trials and a strategic pivot towards type 1 diabetes and autoimmune diseases.
March 17, 2025 Sana Biotechnology Reports Promising Fourth Quarter and Full Year 2024 Results Sana Biotechnology reported its Q4 and full year 2024 results, highlighting advancements in diabetes treatment and CAR T cell therapies. CEO Steve Harr expressed optimism about their UP421 program's promising clinical data, while the company is also progressing with SC451 and innovative delivery technologies.
March 11, 2025 SWOT Analysis of Sana Biotechnology Inc. in 2025 This SWOT analysis of Sana Biotechnology Inc. in 2025 reveals its strong technologies and experienced team, while highlighting challenges in financial sustainability and competition. The company has opportunities in the growing market for engineered cell therapies but must navigate regulatory hurdles.
February 24, 2025 Sana Biotechnology Set to Present at Cowen 45th Annual Health Care Conference Sana Biotechnology will present at the Cowen 45th Annual Health Care Conference on March 3, 2025, sharing insights on its innovative engineered cell therapies. CEO Steve Harr will discuss the company's strategy, recent advancements, and commitment to patient treatment. The presentation will be accessible via live webcast, promoting engagement with investors and the healthcare community.
November 08, 2024 Sana Biotechnology Inc. Reports Q3 2024 Financial Results and Strategic Developments Sana Biotechnology Inc. reported a net loss of $59.92 million in Q3 2024, a significant drop from the previous year. The company is strategically repositioning to focus on high-potential therapeutic areas while facing ongoing financial challenges. Despite losses, Sana remains committed to its innovative research and development efforts.
August 08, 2024 Sana Biotechnology Inc. Reports Q2 2024 Financial Results: A Comprehensive Overview Sana Biotechnology Inc. reports a reduced net loss of $50.29 million for Q2 2024, highlighting progress in multiple clinical trials. The company focuses on engineered cell therapies while managing operational costs and maintaining sufficient liquidity for ongoing operations.
May 08, 2024 Sana Biotechnology Inc. Reports Q1 2024 Financial Results: Key Insights and Developments Sana Biotechnology Inc. reported a net income loss of $107.4 million in Q1 2024, attributed to ongoing investments in R&D. The company is engaged in multiple clinical trials and anticipates continued losses as it focuses on innovative therapies and funding requirements.
